MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.4920
-0.0080
-1.60%
After Hours: 0.4950 +0.003 +0.61% 19:58 07/11 EDT
OPEN
0.5000
PREV CLOSE
0.5000
HIGH
0.5128
LOW
0.4850
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
3.179
52 WEEK LOW
0.3055
MARKET CAP
120.74M
P/E (TTM)
-1.2829
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SGMO last week (0630-0704)?
Weekly Report · 6d ago
Analysts’ Top Healthcare Picks: Sangamo Biosciences (SGMO), Alpha Cognition Inc (ACOG)
TipRanks · 06/30 16:10
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)
TipRanks · 06/30 12:20
Weekly Report: what happened at SGMO last week (0623-0627)?
Weekly Report · 06/30 09:22
Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments
TipRanks · 06/27 16:15
Truist Financial Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)
TipRanks · 06/25 11:36
Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 06/24 16:47
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Benzinga · 06/24 16:40
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.